SOPHiA GENETICS (NASDAQ: SOPH) exec sells 216 shares to cover taxes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported small insider sales tied to tax obligations. On July 6, 2026, he sold a total of 216 Ordinary Shares in open-market transactions at prices between $5.0251 and $5.0862 per share.

According to the footnotes, these were non-discretionary “sell to cover” trades executed to satisfy taxes from restricted stock units that vested on July 2 and July 3, 2026. After these transactions, he continues to hold 147,948 Ordinary Shares directly.

Insider Trade Summary

Net Seller: 216 shares ($1,087)

Net Sell 3 txns

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 216 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	138	$5.0251	$693.46
Sale	Ordinary Shares	47	$5.0251	$236.18
Sale	Ordinary Shares	31	$5.0862	$157.67

Holdings After Transaction: Ordinary Shares — 148,026 shares (Direct)

Footnotes (1)

Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Key Figures

Shares sold: 216 shares Sale prices: $5.0251–$5.0862 per share Post-transaction holdings: 147,948 shares +1 more

4 metrics

Shares sold 216 shares Total Ordinary Shares sold on July 6, 2026

Sale prices $5.0251–$5.0862 per share Open-market sale prices for Ordinary Shares

Post-transaction holdings 147,948 shares Ordinary Shares held directly after the transactions

Net share change -216 shares Net sell activity in this Form 4

Key Terms

Ordinary Shares, restricted stock units, sell to cover, open-market sale

4 terms

Ordinary Shares financial

"The transactions involved Ordinary Shares of SOPHiA GENETICS SA."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

restricted stock units financial

"tax obligations in connection with the vesting of restricted stock units on July 2, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"The sales were effected as a "sell to cover" transaction and do not represent discretionary trades."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 04:04 PM Accepted by SEC EDGAR 07/07/2026 - 04:03 PM

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) disclose for Kevin Puylaert?

SOPHiA GENETICS disclosed that Chief Sales Officer Kevin Puylaert sold 216 Ordinary Shares. The sales occurred on July 6, 2026, in open-market transactions and were linked to tax obligations arising from recent restricted stock unit vesting.

How many SOPHiA GENETICS (SOPH) shares did the executive sell and at what prices?

Kevin Puylaert sold 216 Ordinary Shares of SOPHiA GENETICS. The reported open-market sale prices ranged from $5.0251 to $5.0862 per share, reflecting several small transactions executed on the same trading date.

Why did SOPHiA GENETICS executive Kevin Puylaert sell 216 shares?

The shares were sold to cover tax obligations from vesting restricted stock units. Footnotes state the July 6, 2026 transactions were “sell to cover” trades tied to RSUs that vested on July 2 and July 3, 2026, not discretionary sales.

Were the SOPHiA GENETICS (SOPH) insider sales discretionary trades?

The trades were not discretionary according to the filing’s footnotes. They describe the transactions as “sell to cover” sales executed in the open market solely to satisfy tax obligations from recent restricted stock unit vesting events.

How many SOPHiA GENETICS (SOPH) shares does Kevin Puylaert hold after the transactions?

Following the July 6, 2026 sales, Kevin Puylaert directly holds 147,948 Ordinary Shares. This post-transaction balance indicates that the 216 shares sold for taxes represent a small portion of his overall direct share ownership.

What type of security was involved in the SOPHiA GENETICS insider sale?

The transactions involved Ordinary Shares of SOPHiA GENETICS SA. These shares were sold in open-market trades and were associated with tax obligations created by the vesting of restricted stock units awarded to the company’s Chief Sales Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE

1180

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	07/06/2026		S		138⁽¹⁾	D	$5.0251	148,026	D
Ordinary Shares	07/06/2026		S		47⁽¹⁾	D	$5.0251	147,979	D
Ordinary Shares	07/06/2026		S		31⁽²⁾	D	$5.0862	147,948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

2. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR